Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms and its potential diagnostic value by L. Yin, R. Wang, X. Ma, K. Jiang, Y. Hu, X. Zhao, L. Zhang, Z. Wang, T. Long, M. Lu, J. Li, Y. Sun

“…DLL3 expression rates were 54.8% in GEP-NECs at the primary site, associated with small cell neuroendocrine carcinoma (SCNEC) (p < 0.001), chemotherapy before baseline (p = 0.015), and at least two NE markers (p = 0.048). …”
Get full text

Effectiveness and Safety of Treatments for Early‐Stage Merkel Cell Carcinoma: A Systematic Review and Meta‐Analysis of Randomized and Non‐Randomized Studies by Yves Paul Vincent Mbous, Rowida Mohamed, Usha Sambamoorthi, Murtuza Bharmal, Khalid M. Kamal, Traci LeMasters, Joanna Kolodney, George A. Kelley

“…ABSTRACT Objective The lack of consensus on the benefits and harms of standard therapies, including surgery (SRx), radiotherapy (RTx), chemotherapy (CTx), and their combinations among early‐stage MCC, prompted this study. …”
Get full text

Mutations in 23S rRNA gene associated with clarithromycin resistance in Helicobacter pylori clinical isolates from Saint-Petersburg by Starkova D.A., Gladyshev N.S., Polev D.E., Egorova S.A., Svarval A.V.

Get full text

The value of MRI in differentiating ovarian clear cell carcinoma from other adnexal masses with O-RADS MRI scores of 4–5 by Lingling Lin, Le Fu, Huawei Wu, Saiming Cheng, Guangquan Chen, Lei Chen, Jun Zhu, Yu Wang, Jiejun Cheng

“…Critical relevance statement CCC has a high incidence rate in Asians and has limited sensitivity to platinum chemotherapy. This comprehensive model improves CCC prediction ability and clinical applicability for facilitating individualised clinical decision-making. …”
Get full text

The global trends and distribution in tumor-infiltrating lymphocytes over the past 49 years: bibliometric and visualized analysis by Beibei Wu, Beibei Wu, Beibei Wu, Ding Luo, Ding Luo, Xuejie Wang, Xuejie Wang, Chen Qiao, Chen Qiao, Rui Li, Jian Liu, Jian Liu

“…Combination therapies; tumor neoantigens; gene editing; dominant population selection of TILs therapy; TILs in Tumor microenvironment; emerging predictive biomarkers; TILs in predicting the efficacy of neoadjuvant chemotherapy and immunotherapy; the relationship between TILs and PD-L1; TIL-based patient stratification; tertiary lymphoid structures; and TIL evaluation through digital pathology and artificial intelligence are identified as key areas of interest.ConclusionsThis analysis highlights the increasing academic focus on tumor-infiltrating lymphocyte research and identifies key recent themes in the field such as prognostic value of TILs, personalized treatments, and combination therapies.…”
Get full text

Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective by Yeh Chen Lee, Nazlin Jivraj, Catherine O’Brien, Tanya Chawla, Eran Shlomovitz, Sarah Buchanan, Jenny Lau, Jennifer Croke, Johane P. Allard, Preeti Dhar, Stephane Laframboise, Sarah E. Ferguson, Neesha Dhani, Marcus Butler, Pamela Ng, Terri Stuart-McEwan, Pamela Savage, Lisa Tinker, Amit M. Oza, Stephanie Lheureux

“…This review summarizes the current literature on the different approaches targeting MBO management including surgical intervention, chemotherapy, total parenteral nutrition, and pharmacological treatment. …”
Get full text

Early tolerance and late persistence as alternative drug responses in cancer by Simona Punzi, Davide Cittaro, Guido Gatti, Gemma Crupi, Oronza A. Botrugno, Antonino Alex Cartalemi, Alon Gutfreund, Caterina Oneto, Valentina Giansanti, Chiara Battistini, Giovanni Santacatterina, Lucrezia Patruno, Ilaria Villanti, Martina Palumbo, Daniel J. Laverty, Francesca Giannese, Alex Graudenzi, Giulio Caravagna, Marco Antoniotti, Zachary Nagel, Ugo Cavallaro, Luisa Lanfrancone, Timothy A. Yap, Giulio Draetta, Nathalie Balaban, Giovanni Tonon

“…Here, we show that human cancer cells elicit a tolerant response when exposed to commonly used chemotherapy regimens, propelled by the pervasive activation of autophagy, leading to the comprehensive activation of DNA damage repair pathways. …”
Get full text

Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation by Xinjun Lu, Qi Zhu, Junfeng Cai, Zuozhong Yang, Guangxiang Gu, Li Pang, Mingye Su, Fapeng Zhang, Haoming Lin, Wenrui Wu, Leibo Xu, Chao Liu

“…However, no synergistic anti-tumor effects were observed with pretransplant ICI immunotherapy when combined with locoregional of TACE, HAIC, RFA and systematic of lenvatinib or sorafenib downstaging treatments, nor with post-transplant adjuvant of systematic or FOLFOX chemotherapy. Further comprehensive studies are needed to balance the dual natural effects of immunotherapy by optimizing downstaging protocols and patient selection to reduce acute rejection and improve long-term survival.…”
Get full text

Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option? by Daniele Fanale, Giuseppe Bronte, Francesco Passiglia, Valentina Calò, Marta Castiglia, Florinda Di Piazza, Nadia Barraco, Antonina Cangemi, Maria Teresa Catarella, Lavinia Insalaco, Angela Listì, Rossella Maragliano, Daniela Massihnia, Alessandro Perez, Francesca Toia, Giuseppe Cicero, Viviana Bazan

“…Some of them showed antiangiogenic and antivascular activity and others showed the ability to overcome multidrug resistance, supporting their possible use in chemotherapy.…”
Get full text

Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLC by Evgenia Taranova, Marianne Aanerud, MD, PhD, Tarje O. Halvorsen, MD, PhD, Kristin T. Killingberg, MD, PhD, Marit Slaaen, MD, PhD, Bjørn H. Grønberg, MD, PhD

“…Methods: Patients received platinum-etoposide-chemotherapy and were randomized to receive TRT of 60 Gy in 40 fractions or 45 Gy in 30 fractions. …”
Get full text

ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress by Jenna L. Carter, Yongwei Su, Eman T. Al-Antary, Jianlei Zhao, Xinan Qiao, Guan Wang, Holly Edwards, Lisa Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Steven A. Buck, Maik Hüttemann, Joshua E. Allen, Varun V. Prabhu, Jay Yang, Jeffrey W. Taub, Yubin Ge

“…Abstract Background Venetoclax + azacitidine is a frontline treatment for older adult acute myeloid leukemia (AML) patients and a salvage therapy for relapsed/refractory patients who have been treated with intensive chemotherapy. While this is an important treatment option, many patients fail to achieve complete remission and of those that do, majority relapse. …”
Get full text

Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis by Jeff Clarke, Xiaofei Wang, Thomas Stinchcombe, Scott J Antonia, Jeffrey Crawford, Neal Ready, Konstantin H Dragnev, Lin Gu, Cameron Wood, James M Isaacs, Liliana Lyniv, Kent Weinhold, Jacob M Kaufman, Eziafa I Oduah, Betty C Tong, Dennis Wigle

“…Patients received two doses of 200 mg pembrolizumab, surgery, standard adjuvant chemotherapy, followed by four doses adjuvant pembrolizumab. …”
Get full text

Evaluation of the association between bevacizumab concentration and clinical outcomes in patients with breast cancer brain metastasis by Chih-Ning Cheng, Yun-Jung Tsai, Huai-Hsuan Chiu, Tom Wei-Wu Chen, Ching-Hung Lin, Yen-Sheng Lu, Ching-Hua Kuo

“…This study aimed to evaluate the exposure-response relationship of bevacizumab in BCBM patients and to explore the improved CNS penetration of chemotherapy by bevacizumab with LM patients. Twenty-two BCBM patients and six LM patients receiving the BEEP regimen were enrolled. …”
Get full text

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design by Haiying Qin, Nirali N Shah, Terry J Fry, Lila Yang, John A Chukinas, Samiksha Tarun, Marie Pouzolles, Christopher D Chien, Lisa M Niswander, Anthony R Welch, Sarah K Tasian, Naomi A Taylor

“…Background Successful development of chimeric antigen receptor (CAR) T cell immunotherapy for children and adults with relapsed/refractory acute myeloid leukemia (AML) is highly desired given their poor clinical prognosis and frequent inability to achieve cure with conventional chemotherapy. Initial experiences with CD19 CAR T cell immunotherapy for patients with B-cell malignancies highlighted the critical impact of intracellular costimulatory domain selection (CD28 vs 4-1BB (CD137)) on CAR T cell expansion and in vivo persistence that may impact clinical outcomes. …”
Get full text

Predicting survival rates: the power of prognostic nomograms in distal cholangiocarcinoma by Jiangfeng Hu, Yuping Shi, Lihua Jin, Suhong Yi, Jinsuo Chen, Dadong Wan, Weixin Ye, Jingnan Chen, Yajing Zhang, Yang Jiang, Bensong Duan, Yuwei Dong

“…Decision curve analysis was used to evaluate the model and its clinical applicability.ResultsThe findings demonstrated that Grade, M stages, Surgery, and Chemotherapy emerged as autonomous prognostic factors for the survival of individuals with dCCA. …”
Get full text

Genomic, transcriptomic, and T cell receptor profiling in stratifying response to first-line chemoradiotherapy or radiotherapy for esophageal squamous cell carcinoma by Xiaqin Zhang, Jianhong Lian, Fukun Chen, Kai Wang, Haoyuan Xue, Sufang Jia, Weili Wang, Zhongkang Li, Hua Liang, Hongwei Li

“…Richness was significantly decreased from pre-treat to post-treat.DiscussionMultiomics analysis provided the basic TCRs dynamics and their genomic and transcriptome association during the radio-chemotherapy of 23 locally advanced ESCC in China, and provided a valuable insights into the heterogeneity and the tumor microenvironment and treatment responses. …”
Get full text

Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo by Zheng Wang, Yu Liu, Yunxia Xu, Lin Lu, Zhen Zhu, Baojie Lv, Xin Fang, Yao Tang, Jinhua Wang, Yu Cheng, Ying Hu, Junwen Lou, Peican Wu, Chendan Liu, Yanjun Liu, Xin Zeng, Qing Xu

“…Currently approved human epidermal growth factor receptor 2 (HER2)-targeted antibody therapies are largely derived from trastuzumab, including trastuzumab-chemotherapy combinations, fixed-dose trastuzumab-pertuzumab combinations, and trastuzumab antibody-drug conjugates. …”
Get full text

Agathisflavone Inhibits Viability and Modulates the Expression of miR-125b, miR-155, IL-6, and Arginase in Glioblastoma Cells and Microglia/Macrophage Activation by Karina Costa da Silva, Irlã Santos Lima, Cleonice Creusa dos Santos, Carolina Kymie Vasques Nonaka, Bruno Solano de Freitas Souza, Jorge Mauricio David, Henning Ulrich, Ravena Pereira do Nascimento, Maria de Fátima Dias Costa, Balbino Lino dos Santos, Silvia Lima Costa

“…Treatment involves chemotherapy and/or radiotherapy; however, there is currently no standard treatment for recurrence, and prognosis remains unfavourable. …”
Get full text

Deep learning-based CT radiomics predicts prognosis of unresectable hepatocellular carcinoma treated with TACE-HAIC combined with PD-1 inhibitors and tyrosine kinase inhibitors by Linan Yin, Ruibao Liu, Wei Li, Shijie Li, Xunbo Hou

“…Abstract Objective To develop and validate a computed tomography (CT)-based deep learning radiomics model to predict treatment response and progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (uHCC) treated with transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors and tyrosine kinase inhibitors (TKIs). …”
Get full text

Evaluation of magnetic resonance thermometry performance during MR-guided hyperthermia treatment of soft-tissue sarcomas in the lower extremities and pelvis by Spyridon N. Karkavitsas, Marianne Göger-Neff, Maria Kawula, Kemal Sumser, Benjamin Zilles, Martin Wadepohl, Guillaume Landry, Christopher Kurz, Wolfgang G. Kunz, Olaf Dietrich, Lars H. Lindner, Margarethus M. Paulides

“…Introduction This study evaluated the performance of magnetic resonance thermometry (MRT) during deep-regional hyperthermia (HT) in pelvic and lower-extremity soft-tissue sarcomas.Materials and methods 17 pelvic (45 treatments) and 16 lower-extremity (42 treatments) patients underwent standard regional HT and chemotherapy. Pairs of double-echo gradient-echo scans were acquired during the MR protocol 1.4 s apart. …”
Get full text